How much revenue does Hainan Haiyao make?

Hainan Haiyao reported 990.70 million CNY in revenue for fiscal year 2024, down 33.0% from 1.48 billion CNY in fiscal year 2023. In Q2 2025 revenue was 243.68 million CNY.

What is Hainan Haiyao's largest business segment?

Manufacturing and Sale of Medicine Preparation, with 443.52 million CNY or 50% of segment revenue in fiscal year 2025. Next: Others (24%) and Sale and Manufacturing of Active Pharmaceutical Ingredients (19%).

Where does Hainan Haiyao make most of its revenue?

China: 92% of revenue by region in fiscal year 2025, followed by Foreign (8%).

What companies are similar to Hainan Haiyao?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Cisen Pharmaceutical Co., Ltd. (603367.SS), Hunan Warrant Pharmaceutical Co.,Ltd (688799.SS), Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ), Youcare Pharmaceutical Group Co., Ltd. (688658.SS).

Hainan Haiyao Co., Ltd. (000566.SZ) Stock

About Hainan Haiyao Co., Ltd.

Hainan Haiyao Co., Ltd. manufactures and sells pharmaceutical products and medical devices in China and internationally. The company offers big health, digestive, anti-infective, respiratory, anti-tumor, vitamins, and chronic disease category products. It also provides active pharmaceutical ingredients and intermediates; traditional Chinese medicine decoction pieces; medical devices, including dis...

At a glance

Hainan Haiyao reported revenue of 990.70 million CNY for fiscal year 2024, down 33.0% from fiscal year 2023, and net income of -1.53 billion CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 243.68 million CNY, up 5.8% from a year before. Its largest business segment, Manufacturing and Sale of Medicine Preparation, brought in 50% of segment revenue in fiscal year 2025; China was the largest region with 92%.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.